These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38214106)

  • 41. A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization.
    Khan I; Lau K; Bnyan R; Houacine C; Roberts M; Isreb A; Elhissi A; Yousaf S
    Pharm Res; 2020 Jun; 37(6):116. PubMed ID: 32488363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells.
    Ramadass SK; Anantharaman NV; Subramanian S; Sivasubramanian S; Madhan B
    Colloids Surf B Biointerfaces; 2015 Jan; 125():65-72. PubMed ID: 25437065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation.
    Levit SL; Gade NR; Roper TD; Yang H; Tang C
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
    Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
    Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
    Ravar F; Saadat E; Gholami M; Dehghankelishadi P; Mahdavi M; Azami S; Dorkoosh FA
    J Control Release; 2016 May; 229():10-22. PubMed ID: 26968799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Optimized Formulation of Tamoxifen-Loaded Niosomes Efficiently Induced Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.
    Akbarzadeh I; Farid M; Javidfar M; Zabet N; Shokoohian B; Arki MK; Shpichka A; Noorbazargan H; Aghdaei HA; Hossein-Khannazer N; Timashev P; Makvandi P; Vosough M
    AAPS PharmSciTech; 2022 Jan; 23(1):57. PubMed ID: 35048234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
    Asik A; Kayabasi C; Ozmen Yelken B; Yılmaz Susluer S; Dogan Sigva ZO; Balcı Okcanoglu T; Saydam G; Biray Avci C; Gunduz C
    Gene; 2018 Mar; 647():213-220. PubMed ID: 29309887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation of formulation variables and excipient interaction on the production of niosomes.
    Sezgin-Bayindir Z; Yuksel N
    AAPS PharmSciTech; 2012 Sep; 13(3):826-35. PubMed ID: 22644706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery.
    Dattani S; Li X; Lampa C; Lechuga-Ballesteros D; Barriscale A; Damadzadeh B; Jasti BR
    Int J Pharm; 2023 Jan; 631():122464. PubMed ID: 36464111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment.
    Manosroi A; Chankhampan C; Manosroi W; Manosroi J
    Eur J Pharm Sci; 2013 Feb; 48(3):474-83. PubMed ID: 23266464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing.
    Obeid MA; Haifawi S; Khadra I
    Int J Pharm X; 2023 Dec; 5():100168. PubMed ID: 36852395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
    Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
    J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics and in vitro anti-skin aging activity of gallic acid loaded in cationic CTAB niosome.
    Chaikul P; Khat-Udomkiri N; Iangthanarat K; Manosroi J; Manosroi A
    Eur J Pharm Sci; 2019 Apr; 131():39-49. PubMed ID: 30735821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoniosomes with controlled release and improved uptake.
    Dehghan S; Naghipour A; Anbaji FZ; Golshanrad P; Mirazi H; Adelnia H; Bodaghi M; Far BF
    Int J Pharm; 2023 Jun; 640():122977. PubMed ID: 37121495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
    Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
    Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
    Nasri N; Saharkhiz S; Dini G; Yousefnia S
    Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation and characterization of EP-liposomes and Span 40-niosomes.
    Ning M; Guo Y; Pan H; Zong S; Gu Z
    Pharmazie; 2006 Mar; 61(3):208-12. PubMed ID: 16599261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
    Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
    Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment.
    Ahmadi S; Seraj M; Chiani M; Hosseini S; Bazzazan S; Akbarzadeh I; Saffar S; Mostafavi E
    Int J Nanomedicine; 2022; 17():6233-6255. PubMed ID: 36531115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.